Skip to main content

It looks like you are visiting from outside the EU. Switch to the US version to see local pricing in USD and local shipping.

Switch to US ($)
Contact +33 (0)3 90 20 54 70

📢 ProteoGenix Loyalty Program is live — Earn points on every online order. Discover the program

🚀 Special Offer🚀Get 25% off on your bioreagent online order (except Micelles and Nanodiscs), with the code: PROTEOSHOP25

📢 New ! Accelerate your Antibody Development with Ready-to-use Stable Cell Pools

Explore Now
Brand: ProteoGenix

Rovalpituzumab Biosimilar – Anti-DLL3 mAb – Research Grade

Clonality:
Monoclonal Antibody
Isotype:
IgG1, kappa

€200.00

+ 200 loyalty points
Size
Clear
  • In Stock
  • Free shipping in EU on orders > €500
  • Wide range of unique reagents
  • Fast worldwide delivery
Rovalpituzumab Biosimilar - Anti-DLL3 mAb - Research Grade

Rovalpituzumab Biosimilar - Anti-DLL3 mAb - Research Grade

Product name Rovalpituzumab Biosimilar - Anti-DLL3 mAb - Research Grade
Source CAS 1613313-01-1
Species Humanized
Purity >85%
Buffer PBS buffer PH7.5
Delivery condition Blue ice (+4°C)
Delivery Time 3-5 days if in stock; 3-5 weeks if production needed
Storage condition store at -80°C
Brand ProteoGenix
Applications ELISA,WB
Aliases /Synonyms Rovalpituzumab,,DLL3,anti-DLL3
Reference PX-TA1397
Note For research use only. Not suitable for clinical or therapeutic use.
Isotype IgG1-kappa
Clonality Monoclonal Antibody
Product name Rovalpituzumab Biosimilar - Anti-DLL3 mAb - Research Grade
Source CAS 1613313-01-1
Species Humanized
Expression system Mammalian cells
Purity >85%
Buffer PBS buffer PH7.5
Delivery condition Blue ice (+4°C)
Delivery Time 3-5 days if in stock; 3-5 weeks if production needed
Storage condition store at -80°C
Brand ProteoGenix
Applications ELISA,WB,,,
Aliases /Synonyms Rovalpituzumab,,DLL3,anti-DLL3
Reference PX-TA1397
Note For research use only. Not suitable for clinical or therapeutic use.
Isotype IgG1-kappa
Clonality Monoclonal Antibody

General information on Anti-DLL3[Homo sapiens] (Rovalpituzumab) Monoclonal Antibody

Rovalpituzumab has been investigated for the treatment of Glioblastoma, Malignant Melanoma, Other Solid Tumors, Small Cell Lung Cancer, and Medullary Thyroid Cancer.

There are no reviews yet.

Be the first to review “Rovalpituzumab Biosimilar – Anti-DLL3 mAb – Research Grade”

Your email address will not be published. Required fields are marked *

Recently viewed products

Loading recently viewed products…

Can’t find what you need?

Our catalog doesn’t cover everything — but our team does. Whether you need a custom antibody, a specific protein variant, or a bulk order, our scientists are here to help.

Contact Our Team Book a Call

Cart (0 Items)

Your cart is currently empty.

View Products